122 related articles for article (PubMed ID: 24048738)
41. Role of the protein kinase BRAF in the pathogenesis of endometriosis.
Santulli P; Marcellin L; Chouzenoux S; Boulard V; Just PA; Nicco C; Chereau C; Tosti C; Chapron C; Batteux F
Expert Opin Ther Targets; 2016 Aug; 20(8):1017-29. PubMed ID: 27087167
[TBL] [Abstract][Full Text] [Related]
42. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
43. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
45. HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.
Budina-Kolomets A; Webster MR; Leu JI; Jennis M; Krepler C; Guerrini A; Kossenkov AV; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Wu H; Yin X; Liu Q; Lu Y; Mills GB; Xu X; George DL; Weeraratna AT; Murphy ME
Cancer Res; 2016 May; 76(9):2720-30. PubMed ID: 26984758
[TBL] [Abstract][Full Text] [Related]
46. Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas.
Shenolikar S
J Clin Invest; 2014 Mar; 124(3):973-6. PubMed ID: 24569370
[TBL] [Abstract][Full Text] [Related]
47. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
Walter L; Heinzerling L
Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057
[TBL] [Abstract][Full Text] [Related]
48. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
Beck D; Niessner H; Smalley KS; Flaherty K; Paraiso KH; Busch C; Sinnberg T; Vasseur S; Iovanna JL; Drießen S; Stork B; Wesselborg S; Schaller M; Biedermann T; Bauer J; Lasithiotakis K; Weide B; Eberle J; Schittek B; Schadendorf D; Garbe C; Kulms D; Meier F
Sci Signal; 2013 Jan; 6(260):ra7. PubMed ID: 23362240
[TBL] [Abstract][Full Text] [Related]
49. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
50. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
Liu R; Liu D; Xing M
J Clin Endocrinol Metab; 2012 Feb; 97(2):E173-82. PubMed ID: 22090271
[TBL] [Abstract][Full Text] [Related]
51. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.
Hu W; Jin L; Jiang CC; Long GV; Scolyer RA; Wu Q; Zhang XD; Mei Y; Wu M
Cell Death Dis; 2013 Nov; 4(11):e914. PubMed ID: 24201813
[TBL] [Abstract][Full Text] [Related]
52. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Søndergaard JN; Nazarian R; Wang Q; Guo D; Hsueh T; Mok S; Sazegar H; MacConaill LE; Barretina JG; Kehoe SM; Attar N; von Euw E; Zuckerman JE; Chmielowski B; Comin-Anduix B; Koya RC; Mischel PS; Lo RS; Ribas A
J Transl Med; 2010 Apr; 8():39. PubMed ID: 20406486
[TBL] [Abstract][Full Text] [Related]
53. BAG-1 modulates the chaperone activity of Hsp70/Hsc70.
Takayama S; Bimston DN; Matsuzawa S; Freeman BC; Aime-Sempe C; Xie Z; Morimoto RI; Reed JC
EMBO J; 1997 Aug; 16(16):4887-96. PubMed ID: 9305631
[TBL] [Abstract][Full Text] [Related]
54. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
55. Neutral analogs of the heat shock protein 70 (Hsp70) inhibitor, JG-98.
Shao H; Gestwicki JE
Bioorg Med Chem Lett; 2020 Mar; 30(5):126954. PubMed ID: 31952963
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
Basile KJ; Le K; Hartsough EJ; Aplin AE
Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
[TBL] [Abstract][Full Text] [Related]
57. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
58. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib.
Pucciarelli D; Lengger N; Takáčová M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Mol Med Rep; 2016 Apr; 13(4):3281-8. PubMed ID: 26936534
[TBL] [Abstract][Full Text] [Related]
59. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Halaban R; Zhang W; Bacchiocchi A; Cheng E; Parisi F; Ariyan S; Krauthammer M; McCusker JP; Kluger Y; Sznol M
Pigment Cell Melanoma Res; 2010 Apr; 23(2):190-200. PubMed ID: 20149136
[TBL] [Abstract][Full Text] [Related]
60. Rescue of cell cycle progression in BRAF
Toress-Collado AX; Nazarian R; Jazirehi AR
Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]